MedTrace Logo

Safety and Intake Effect of EPs® 7630 (an Extract of the Roots of Pelargonium Sidoides)

NCT02174653 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 720

Last updated 2017-01-12

No results posted yet for this study

Summary

The aim of the study is to evaluate the safety of the intake of EPs® 7630 during a long-term (4 months) medication. The protective effects of EPs®7630 and its effects during a cold episode will also be studied.

Conditions

  • Common Cold

Interventions

DRUG

EPs® 7630

20 mg EPs® 7630 film-coated tablets during 4 months Orally intake three times a day (in the morning, midday and evening)

DRUG

Placebo

Control: Placebo film coated tablets during 4 months Orally intake three times a day (in the morning, midday and evening)

Sponsors & Collaborators

  • Dr. Willmar Schwabe GmbH & Co. KG

    lead INDUSTRY

Principal Investigators

  • Moutaz SM Jawad, M.B., B.Ch., FRCP · Common Cold Centre, Cardiff School of Biosciences, Cardiff University

Study Design

Allocation
RANDOMIZED
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-03-31
Primary Completion
2015-07-31
Completion
2016-08-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02174653 on ClinicalTrials.gov